Tumor genetics studies have revealed that somatic mutations in KRAS (> 90% of cases), TP53 (60-70%), SMAD4 (30-40%), and CDKN2A (30-40%) are characteristic molecular genetic features of the vast majority of PC [274]. This evidence concerns the gene KRAS and neoplasm.